Drugs / Hepalatide
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03023787 | Aug → Dec 2016 | chronic hepatitis B virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02612506 | Oct 2015 → Aug 2016 | chronic hepatitis B virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06505928 | Dec 2024 → May 2026 overdue | hepatitis D virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05827146 | Oct 2023 → Jan 2024 | hepatitis D virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05244057 | Aug 2022 → Jun 2024 | chronic hepatitis B virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04426968 | Jun 2021 → Nov 2023 | chronic hepatitis B virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07309380 | Apr 2026 → Jun 2027 expected | hepatitis D virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04662164 Comparator | Dec 2025 | type 2 diabetes mellitus | Shanghai HEP Pharmaceutical Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hepalatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06505928 ↗ |
| Action | Inhibit | “Bile acid transporter inhibitor” CHEMBL4650398 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4650398 ↗ |
| Route | Subcutaneous | “abdominal subcutaneous injection” NCT02612506 ↗ |
| Target | SLC10A1 | “Bile acid transporter inhibitor” CHEMBL4650398 ↗ |